CIK: 0002106939
Total reported value
$187.9M
Reporting period: 2026-06-30 · Number of holdings: 75
PSP Research LLC disclosed 75 holdings in its latest 13F filing for the period ending 2026-06-30, with total reported value of $187.9M and a quarterly turnover rate of 43.2%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "P"
PSP Research LLC's disclosed holdings carry a Herfindahl concentration index of 0.372 — mathematically equivalent to about 3 equally-sized positions, well below its 75 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 5.22), with a handful of outsized bets alongside many smaller positions.
Recent activity leans toward adding more aggressively to already-large existing positions than to newly initiated ones (a 25.6 percentage-point tilt) — a pattern consistent with a momentum-following approach.
Sector classification currently covers about 5% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add XBI
+100.1% $53.8M
Sold out SERA
Sold out TYRA
Sold out ASND
Sold out CYTK
Sold out AGIO
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 48.01% | +22.26% | +100.07% | |
| 2 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 37.51% | — | — | |
| 3 | RPRX | Royalty Pharma plc | Stock-Healthcare | 0.33% | -0.04% | — | |
| 4 | NRIX | Nurix Therapeutics INC | Stock-Other | 0.32% | +0.01% | -12.89% | |
| 5 | INCY | Incyte CORP | Stock-Healthcare | 0.32% | -0.03% | — | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.32% | -0.01% | — | |
| 7 | IRON | Disc Medicine INC | Stock-Other | 0.31% | — | — | |
| 8 | RAPP | Rapport Therapeutics INC | Stock-Other | 0.31% | — | — | |
| 9 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.30% | -0.03% | -23.08% | |
| 10 | TRVI | Trevi Therapeutics INC | Stock-Other | 0.30% | +0.05% | — | |
| 11 | GLUE | Monte Rosa Therapeutics INC | Stock-Other | 0.30% | -0.03% | -17.86% | |
| 12 | TGTX | Tg Therapeutics INC | Stock-Healthcare | 0.29% | -0.02% | -23.08% | |
| 13 | HALO | Halozyme Therapeutics INC | Stock-Healthcare | 0.29% | — | -12.78% | |
| 14 | IONS | Ionis Pharmaceuticals INC | Stock-Healthcare | 0.29% | — | — | |
| 15 | PHVS | Pharvaris N.V. | Stock-Other | 0.28% | — | -25.00% | |
| 16 | ARQT | Arcutis Biotherapeutics INC | Stock-Other | 0.27% | — | — | |
| 17 | AUPH | Aurinia Pharmaceuticals INC | Stock-Other | 0.27% | — | — | |
| 18 | NBIX | Neurocrine Biosciences INC | Stock-Healthcare | 0.27% | — | -22.04% | |
| 19 | IMVT | Immunovant INC | Stock-Other | 0.27% | — | -32.29% | |
| 20 | ACAD | Acadia Pharmaceuticals INC | Stock-Healthcare | 0.27% | — | — | |
| 21 | PTCT | Ptc Therapeutics INC | Stock-Healthcare | 0.26% | — | — | |
| 22 | CLDX | Celldex Therapeutics INC | Stock-Other | 0.26% | — | — | |
| 23 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.26% | — | — | |
| 24 | DFTX | Definium Therapeutics INC | Stock-Other | 0.25% | -0.22% | -71.26% | |
| 25 | COGT | Cogent Biosciences INC | Stock-Other | 0.25% | — | — | |
| 26 | KYMR | Kymera Therapeutics INC | Stock-Other | 0.24% | — | -36.51% | |
| 27 | DYN | Dyne Therapeutics INC | Stock-Other | 0.24% | — | — | |
| 28 | ALNY | Alnylam Pharmaceuticals INC | Stock-Healthcare | 0.23% | — | — | |
| 29 | TARS | Tarsus Pharmaceuticals INC | Stock-Other | 0.23% | — | — | |
| 30 | SNDX | Syndax Pharmaceuticals INC | Stock-Other | 0.23% | — | — | |
| 31 | EXEL | Exelixis INC | Stock-Healthcare | 0.23% | — | -33.04% | |
| 32 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.22% | — | — | |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.22% | — | -20.00% | |
| 34 | ✓ | Ascendis Pharma A/s | Stock-Other | 0.21% | +0.21% | NEW | |
| 35 | LQDA | Liquidia CORP | Stock-Other | 0.21% | +0.21% | NEW | |
| 36 | STOK | Stoke Therapeutics INC | Stock-Other | 0.21% | — | — | |
| 37 | VKTX | Viking Therapeutics INC | Stock-Healthcare | 0.21% | -0.14% | -33.33% | |
| 38 | IMNM | Immunome INC | Stock-Other | 0.20% | — | -10.00% | |
| 39 | PTGX | Protagonist Therapeutics INC | Stock-Other | 0.20% | — | — | |
| 40 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.19% | — | -29.99% | |
| 41 | ELVN | Enliven Therapeutics INC | Stock-Other | 0.19% | — | — | |
| 42 | SYRE | Spyre Therapeutics INC | Stock-Other | 0.19% | +0.01% | -22.47% | |
| 43 | NTLA | Intellia Therapeutics INC | Stock-Other | 0.18% | — | -25.65% | |
| 44 | MDGL | Madrigal Pharmaceuticals INC | Stock-Healthcare | 0.17% | — | — | |
| 45 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.17% | -0.14% | -44.44% | |
| 46 | ALKS | Alkermes plc | Stock-Healthcare | 0.17% | +0.02% | — | |
| 47 | TNGX | Tango Therapeutics INC | Stock-Other | 0.17% | — | -30.56% | |
| 48 | ARDX | Ardelyx INC | Stock-Other | 0.16% | -0.18% | -25.00% | |
| 49 | VERA | Vera Therapeutics INC | Stock-Other | 0.16% | -0.12% | -30.00% | |
| 50 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 0.16% | -0.17% | -50.00% |
Performance for Q3 2026
—
Performance Last 4 Quarters
—
Based on 0 months of available history
Based on 46% of reported portfolio value with available pricing
PSP Research LLC's most significant position changes for 2026-06-30: Sold out: Sera Prognostics Inc-a (SERA); Sold out: Tyra Biosciences INC (TYRA); Sold out: Ascendis Pharma A/S (ASND); Sold out: Cytokinetics INC (CYTK); Sold out: Agios Pharmaceuticals INC (AGIO).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | +22.3% | +100.07% | Add |
| 2 | ✓ | Ascendis Pharma A/s | +0.2% | NEW | New buy |
| 3 | LQDA | Liquidia CORP | +0.2% | NEW | New buy |
| 4 | KRYS | Krystal Biotech INC | +0.1% | NEW | New buy |
| 5 | AVBP | Arrivent Biopharma INC | +0.1% | NEW | New buy |
| 6 | JAZZ | Jazz Pharmaceuticals plc | +0.1% | NEW | New buy |
| 7 | RVMD | Revolution Medicines INC | +0.1% | NEW | New buy |
| 8 | RYTM | Rhythm Pharmaceuticals INC | +0.1% | NEW | New buy |
| 9 | DNLI | Denali Therapeutics INC | +0.1% | NEW | New buy |
| 10 | ARWR | Arrowhead Pharmaceuticals In | +0.1% | NEW | New buy |
| 11 | SRRK | Scholar Rock Holding CORP | +0.1% | NEW | New buy |
| 12 | CTMX | Cytomx Therapeutics INC | +0.1% | NEW | New buy |
| 13 | TRVI | Trevi Therapeutics INC | +0.1% | — | Unchanged |
| 14 | ALKS | Alkermes plc | 0% | — | Unchanged |
| 15 | NRIX | Nurix Therapeutics INC | 0% | -12.89% | Trim |
| 16 | SYRE | Spyre Therapeutics INC | 0% | -22.47% | Trim |
| 17 | RAPP | Rapport Therapeutics INC | — | — | Unchanged |
| 18 | ARGX | Argenx Se - Adr | 0% | — | Unchanged |
| 19 | TGTX | Tg Therapeutics INC | 0% | -23.08% | Trim |
| 20 | RARE | Ultragenyx Pharmaceutical In | 0% | -23.08% | Trim |
| 21 | INCY | Incyte CORP | 0% | — | Unchanged |
| 22 | GLUE | Monte Rosa Therapeutics INC | 0% | -17.86% | Trim |
| 23 | RPRX | Royalty Pharma plc | 0% | — | Unchanged |
| 24 | CMPX | Compass Therapeutics INC | -0.1% | EXIT | Sold out |
| 25 | VERA | Vera Therapeutics INC | -0.1% | -30.00% | Trim |
| 26 | SMMT | Summit Therapeutics INC | -0.1% | EXIT | Sold out |
| 27 | CMPS | Compass Pathways PLC | -0.1% | -74.65% | Trim |
| 28 | KNSA | Kiniksa Pharmaceuticals International, plc | -0.1% | -44.44% | Trim |
| 29 | VKTX | Viking Therapeutics INC | -0.1% | -33.33% | Trim |
| 30 | 4XC1 | Kalvista Pharmaceuticals INC | -0.2% | EXIT | Sold out |
| 31 | LEGN | Legend Biotech Corp-adr | -0.2% | EXIT | Sold out |
| 32 | APGE | Apogee Therapeutics INC | -0.2% | EXIT | Sold out |
| 33 | UTHR | United Therapeutics CORP | -0.2% | EXIT | Sold out |
| 34 | KOD | Kodiak Sciences INC | -0.2% | -40.00% | Trim |
| 35 | CELC | Celcuity INC | -0.2% | EXIT | Sold out |
| 36 | CRSP | CRISPR Therapeutics AG | -0.2% | -47.37% | Trim |
| 37 | DNTH | Dianthus Therapeutics INC | -0.2% | -50.00% | Trim |
| 38 | MIRM | Mirum Pharmaceuticals INC | -0.2% | -50.00% | Trim |
| 39 | ARDX | Ardelyx INC | -0.2% | -25.00% | Trim |
| 40 | ERAS | Erasca INC | -0.2% | EXIT | Sold out |
| 41 | BBIO | Bridgebio Pharma INC | -0.2% | -50.00% | Trim |
| 42 | AXSM | Axsome Therapeutics INC | -0.2% | -64.85% | Trim |
| 43 | DFTX | Definium Therapeutics INC | -0.2% | -71.26% | Trim |
| 44 | INBX | Inhibrx Biosciences INC | -0.3% | EXIT | Sold out |
| 45 | PRAX | Praxis Precision Medicines I | -0.3% | EXIT | Sold out |
| 46 | AGIO | Agios Pharmaceuticals INC | -0.4% | EXIT | Sold out |
| 47 | CYTK | Cytokinetics INC | -0.4% | EXIT | Sold out |
| 48 | ASND | Ascendis Pharma A/S | -0.4% | EXIT | Sold out |
| 49 | TYRA | Tyra Biosciences INC | -0.4% | EXIT | Sold out |
| 50 | SERA | Sera Prognostics Inc-a | -3.4% | EXIT | Sold out |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-06-30 | 2026-07-09 | 13F-HR | View on EDGAR |
| 2026-03-31 | 2026-04-17 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-06 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0002023744
Total reported value
$187.9M
232 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001643569
Total reported value
$187.9M
17 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001388788
Total reported value
$187.8M
6 stks
2026-03-31
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000096223
Total reported value
$14.6B
1,692 stks
2026-03-31
1 of the top 5 holdings overlap, including Ss Spdr S&p Biotech ETF
CIK 0000098758
Total reported value
$681.7M
88 stks
2026-03-31
1 of the top 5 holdings overlap, including Royalty Pharma plc
CIK 0000732847
Total reported value
$443.9M
85 stks
2026-03-31
1 of the top 5 holdings overlap, including Ishares 0-3 Month Treasury B